Skip to main content

Advertisement

SpringerLink
Log in

Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes—a case series and literature review

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regarding the use of this class in patients with acromegaly and diabetes.

Methods

Reporting data regarding patients with acromegaly and diabetes under treatment with SGLT2i.

Results

29 acromegalic patients with diabetes were identified. Treatment with SGLT-2i was documented in nine patients, out of them 5 females and 4 males with a mean age (SD) of 61 ± 12 yr. The mean (SD) duration of treatment with SGLT2i was 27.5 ± 7.3 months. Mean HbA1c before and after SGLT-2i initiation was 8.1 ± 1.1 and 7.0 ± 0.9% respectively. Mean IGF-1 level (SD) before SGLT-2i initiation was 177 ± 68 ng/mL and the mean GH level (SD) was 0.7 ± 0.5 µg/L. All nine patients are still under treatment with SGLT2i and none of them had reported any adverse reaction related to SGLT2i.

Conclusions

The present article provides us for the first time with new data regarding the use of SGLT2i among acromegalic patients with diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. L. Katznelson, E.R. Laws, S. Melmed et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)

    Article  CAS  Google Scholar 

  2. M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268–332 (2019)

    Article  Google Scholar 

  3. B. Zinman, C. Wanner, J.M. Lachin,EMPA-REG OUTCOME Investigators et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)

    Article  CAS  Google Scholar 

  4. J.J.V. McMurray, D.L. DeMets, S.E. Inzucchi, L. Køber, M.N. Kosiborod, A.M. Langkilde, F.A. Martinez, O. Bengtsson, P. Ponikowski, M.S. Sabatine, M. Sjöstrand, S.D. Solomon,DAPA-HF Committees and Investigators, A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur. J. Heart Fail. 21, 665–675 (2019)

    Article  CAS  Google Scholar 

  5. C. Wanner, H.J.L. Heerspink, B. Zinman, S.E. Inzucchi, A. Koitka-Weber, M. Mattheus, S. Hantel, H.J. Woerle, U.C. Broedl, M. von Eynatten, P.H. Groop,EMPA-REG OUTCOME Investigators, Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J. Am. Soc. Nephrol. 29, 2755–2769 (2018)

    Article  CAS  Google Scholar 

  6. S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27, 470–483 (2016)

    Article  CAS  Google Scholar 

  7. M. Quarella, D. Walser, M. Brändle, J.Y. Fournier, S. Bilz, Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly. J. Clin. Endocrinol. Metab. 102, 1451–1453 (2017)

    Article  Google Scholar 

  8. E.A. Nyenwe, A.E. Kitabchi, The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism 65, 507–521 (2016)

    Article  CAS  Google Scholar 

  9. J. Rosenstock, E. Ferrannini, Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638–1642 (2015)

    Article  CAS  Google Scholar 

  10. N. Fleming, P.S. Hamblin, D. Story, E.I. Ekinci, Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose cotransporter 2 inhibitors. J. Clin. Endocrinol. Metab. 1, 105 dgaa200 (2020). https://doi.org/10.1210/clinem/dgaa200

    Article  Google Scholar 

  11. E. Ferrannini, E. Muscelli, S. Frascerra et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest 124, 499–508 (2014)

    Article  CAS  Google Scholar 

  12. C. Saponaro, F. Pattou, C. Bonner, SGLT2 inhibition and glucagon secretion in humans. Diabetes Metab. 44, 383–385 (2018)

    Article  CAS  Google Scholar 

  13. G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500–1508 (2009)

    Article  CAS  Google Scholar 

  14. A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Reséndiz, M. Ruffin, Y. Chen, M. Sheppard, P.C.S. Group, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014)

    Article  CAS  Google Scholar 

  15. W.M. Drake, S.V. Rowles, M.E. Roberts, F.K. Fode, G.M. Besser, J.P. Monson, P.J. Trainer, Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol. 149, 521–527 (2003)

    Article  CAS  Google Scholar 

  16. Fleseriu, M., Biller, B.M.K., Freda, P.U., Gadelha, M.R., Giustina, A., Katznelson, L., Molitch, M.E., Samson, S.L., Strasburger, C.J., van der Lely, A.J., Melmed, S. A Pituitary Society update to acromegaly management guidelines. (2020) https://doi.org/10.1007/s11102-020-01091-7

  17. P. Ocampo, J.M. Duarte, R. Barcia, C. Arévalo, Association between diabetic ketoacidosis and acromegaly. Medicine 78, 131–133 (2018)

    CAS  Google Scholar 

  18. A. Herrero-Ruiz, H.S. Villanueva-Alvarado, J.J. Corrales-Hernández, C. Higueruela-Mínguez, J. Feito-Pérez et al. Coexistence of GH-producing pituitary macroadenoma and meningioma in a patient with multiple endocrine neoplasia type 1 with hyperglycemia and ketosis as first clinical sign. Case Rep. Endocrinol. 2017, 2390797 (2017). https://doi.org/10.1155/2017/2390797

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. J. Weiss, A.J. Wood, J.D. Zajac, M. Grossmann, S. Andrikopoulos, E.I. Ekinci, Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use. Diabetes Res. Clin. Pract. 134, 29–37 (2017)

    Article  CAS  Google Scholar 

  20. H. Inaba, T. Funahashi, H. Ariyasu et al. Diabetic ketoacidosis in a patient with acromegaly and central diabetes insipidus treated with octreotide long-acting release. Diabetol. Int 10, 237–242 (2017)

    Article  Google Scholar 

  21. N. Yoshida, H. Goto, H. Suzuki, K. Nagasawa, A. Takeshita et al. Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute. Eur. J. Endocrinol. 169, 127–132 (2013)

    Article  CAS  Google Scholar 

  22. R.V. Dosi, R.D. Patell, P.J. Shah et al. Diabetic ketoacidosis: an unusual presentation of acromegaly. BMJ Case Rep. 11, bcr2013010198 (2013)

    Google Scholar 

  23. H.J. Jiang, W.W. Hung, P.J. Hsiao, A case of acromegaly complicated with diabetic ketoacidosis, pituitary apoplexy, and lymphoma. Kaohsiung J. Med Sci. 29, 687–690 (2013)

    Article  Google Scholar 

  24. P. Palakawong, R. Arakaki, Diabetic ketoacidosis in acromegaly: a case report. Endocr. Pract. 27, 1–15 (2012)

    Article  Google Scholar 

  25. P. Mewawalla, G. Jaiswal, M. Moustakakis et al. Refractory DKA as first presentation of acromegaly and a potential role for continuous venovenous hemofiltration in its successful management. Conn. Med. 75, 405–407 (2011)

    PubMed  Google Scholar 

  26. M. Waterhouse, I. Sabin, N. Plowman, S. Akker, T.A. Chowdhury, A “growing cause” of diabetic ketoacidosis. BMJ Case Rep. 11, 2008.1226 (2009)

    Google Scholar 

  27. Y.L. Chen, C.P. Wei, C.C. Lee et al. Diabetic ketoacidosis in a patient with acromegaly. J. Formos. Med. Assoc. 106, 788–791 (2007)

    Article  CAS  Google Scholar 

  28. M. Lakhotia, R. Mathur, H. Singh et al. Diabetic ketosis as a presenting feature of acromegaly. J. Assoc. Physicians India 55, 377–378 (2007)

    CAS  PubMed  Google Scholar 

  29. C. Erem, H.O. Ersöz, K. Ukinç et al. Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine 30, 145–149 (2006)

    Article  CAS  Google Scholar 

  30. B. Kopff, S. Mucha, B.H. Wolffenbuttel et al. Diabetic ketoacidosis in a patient with acromegaly. Med. Sci. Monit. 7, 142–147 (2001)

    CAS  PubMed  Google Scholar 

  31. S.A. Westphal, Concurrent diagnosis of acromegaly and diabetic ketoacidosis. Endocr. Pract. 6, 450–452 (2000)

    CAS  PubMed  Google Scholar 

  32. C.C. Szeto, K.Y. Li, G.T. Ko et al. Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance. Int. J. Clin. Pract. 51, 476–477 (1997)

    CAS  PubMed  Google Scholar 

  33. J.R. Katz, R. Edwards, M. Khan, G.S. Conway, Acromegaly presenting with diabetic ketoacidosis. Postgrad. Med. J. 72, 682–683 (1996)

    Article  CAS  Google Scholar 

  34. J. Vidal Cortada, J.I. Conget Donlo, M.P. Navarro Téllez, I. Halperin Rabinovic, E. Vilardell Latorre, Diabetic ketoacidosis as the first manifestation of acromegaly. An. Med. Interna 12, 76–78 (1995)

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Clalit Medical Health Care Services, Kiryat Bialik, Haifa and Western Galilee District, Israel

    Adnan Zaina, Ali Abid, Eldad Arad & Elena Golden

  2. Bar-Ilan Faculty of Medicine, Safed, Israel

    Adnan Zaina

  3. Division of Neurosurgery, Galilee Medical Center, Nahariya, Israel

    Yuval Grober

  4. Neurology Department, Galilee Medical Center Bar-Ilan Faculty of Medicine, Safed, Israel

    Samih Badarny

Authors
  1. Adnan Zaina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuval Grober
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Abid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eldad Arad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Golden
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samih Badarny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adnan Zaina.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaina, A., Grober, Y., Abid, A. et al. Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes—a case series and literature review. Endocrine 73, 65–70 (2021). https://doi.org/10.1007/s12020-021-02718-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-021-02718-w

Keywords

Search

Navigation